Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Gondwe, Y.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Kudowa, E.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Tomoka, T.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Kasonkanji, E.D.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Kaimila, B.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Zuze, T.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Mumba, N.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Kimani, S.
    • Other Affiliation: University of Utah
  • Mulenga, M.
    • Other Affiliation: Malawi Ministry of Health
  • Chimzimu, F.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Kampani, C.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Randall, C.
    • Affiliation: School of Medicine, Department of Pathology and Laboratory Medicine
  • Lilly, A.
    • Affiliation: School of Medicine, Department of Pathology and Laboratory Medicine
  • Gopal, S.
    • Other Affiliation: National Cancer Institute Center for Global Health
  • Fedoriw, Y.
    • Affiliation: School of Medicine, UNC Project-Malawi
  • Painschab, M.
    • Affiliation: School of Medicine, UNC Project-Malawi
Abstract
  • Access to antiretroviral therapy (ART) led to epidemiological changes in human immunodeficiency virus (HIV) associated lymphoma in high-income countries such as reductions in diffuse large B-cell lymphoma (DLBCL) and stable or increased Hodgkin lymphoma (HL) and Burkitt lymphoma (BL). In 2016, Malawi implemented a universal ART (UART) policy, expanding ART eligibility to all persons living with HIV (PLWH). We compare the distribution of lymphoma subtypes and baseline HIV and prognostic characteristics for lymphoma patients in Malawi before and after implementation of UART. We enrolled patients with pathologically confirmed incident lymphoproliferative disorders into a observational clinical cohort. At diagnosis, a comprehensive clinicopathological evaluation was performed. Of 412 participants, 156 (38%) were pre-UART (2013-June 2016) and 256 (62%) post-UART (July 2016-2020). HIV prevalence was 50% in both groups. The most common pre-UART diagnoses were DLBCL [75 (48%)], low-grade non-Hodgkin lymphoma (NHL) [19 (12%)], HL [17 (11%)] and, BL [13 (8%)]. For post-UART they were DLBCL [111 (43%)], NHL [28 (11%)], BL [27 11%)] and, HL [20 (8%)]. Among PLWH, 44 (57%) pre-UART initiated ART prior to lymphoma diagnosis compared to 99 (78%) post-UART (p = 0.02). HIV-ribonucleic acid was suppressed <1000 copies/mL in 56% (33/59) pre-UART and 71% (73/103) post-UART (p = 0.05). CD4 T-cell counts were similar for both groups. We observed similar findings in the subset of participants with DLBCL. Overall, there were no significant changes in incident lymphoma subtypes (p = 0.61) after implementation of UART, but HIV was better controlled. Emerging trends bear monitoring and may have implications for prognosis and health system priority setting.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • CC0 1.0 Universal
Journal title
  • PLoS ONE
Journal volume
  • 17
Journal issue
  • 9-Sep
Language
  • English
Version
  • Publisher
ISSN
  • 1932-6203

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details journal.pone.0273408.pdf 2022-10-07 Public Download